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Abstract
Background
While Beta blockers (BB) and Angiotensin converting enzyme
inhibitors/Angiotensin receptor blockers (ACEinh/ARB) are important components
in advanced heart failure (HF) therapy, their use after left ventricular assist device
(LVAD) implantation remains controversial. Concern has been raised about
possible adverse effects of BB on right ventricular (RV) function while tolerance
and efficacy/outcome data for ACEinh are lacking. This study aimed to
characterize the use of medical therapy post-LVAD implantation and to evaluate its
safety and efficacy.
Methods
Demographic, clinical and echocardiographic variables of patients implanted with a
continuous-flow LVAD between 2012 and 2015 at a single center were
retrospectively reviewed. Mortality and HF hospitalizations were followed from 618 months’ post-implant.
Results
Of a total of 98 patients, the mean age was 57 years, 81% were men and 61% had
ischemic disease. While the use of diuretics decreased considerably post LVAD,
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over 50% continued to require diuretics. At 6th month post-implantation, 73% of
patients were on BB, and these patients had significantly lower proBNP at 6 and
12 months follow up. Despite significant prevalence of RV dysfunction in the cohort
(>75% at 6 months), there was no significant difference in HF hospitalizations
based on BB use (14% vs 15%) and instead a trend towards less deaths in those
on BB (6% vs 15%). ACEinh/ARB use was likewise common at 6 month (61%)
and these patients had lower pro B-type natriuretic peptide (proBNP) at 6 and 12
months, lower right atrial (RA) pressures (9 vs 12 mmHg, p=0.03), and a
significantly lower mortality—a finding which remained significant on multivariate
analysis.
Conclusion
The use of ACEinh/ARB appeared to be associated with subsequent improved
survival, lower proBNP and RA pressures. The use of BB post-LVAD appears safe
and was associated with a lower proBNP, even in a patient population with a
significant prevalence of RV dysfunction.
Keywords: Left ventricular assist device, advanced heart failure management,
heart failure hospitalization
Abbreviations: BB= Beta blockers, ACEinh/ARB= Angiotensin converting enzyme
inhibitors/Angiotensin receptor blockers, RV= right ventricle, RA= right atrium,
LVAD= left ventricular assist device, CHF= congestive heart failure, proBNP= proB-type natriuretic peptide, GDMT= goal directed medical therapy, NYHA= New
York Heart Association, INTERMACS= Interagency Registry for Mechanically
Assisted Circulatory Support, MAP= mean arterial pressure, LDH= lactate
dehydrogenase, LVEDD= left ventricular end diastolic diameter, AI= aortic
insufficiency, MR= mitral regurgitation, TR= tricuspid regurgitation

Background
While reverse remodeling and optimal heart failure medical therapy is recognized
as an important component in the management of patients with advanced heart
failure (1), this goal directed medical therapy (GDMT) is often not given to patients
following Left Ventricular Assist Device (LVAD) implantation and its use post-LVAD
implantation remains controversial (2). Recipients of mechanical support have
advanced heart failure and are likely to have a similar neurohormonal milieu to
other advanced heart failure patients (3,4). Furthermore the right side of the heart
is unsupported and the addition of the device may lead to worsening of right
ventricular (RV) dysfunction following LVAD implantation due to septal shift and
increased flow to the RV. Hence these patients may continue to suffer from
adverse cardiovascular comorbidities such as ongoing fluid retention leading to
heart failure hospitalizations. Patients post implant may therefore potentially derive
benefit from angiotensin system and beta blockade which might improve their
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quality of life and reduce hospitalizations and adverse events. Such therapy also
results in better blood pressure control hence decreasing the incidence of stroke
(5) on LVAD support. Furthermore, neurohormonal antagonists, beta blockers, and
aldosterone antagonists all significantly facilitate ventricular reverse remodeling
and reduce fibrosis leading to myocardial recovery and subsequent explantation in
some cases (6,7). Despite these potential benefits, concerns have been raised
about the safety of GDMT, due to possible deleterious effects of beta-blockers on
right ventricular (RV) function after LVAD implantation as well concerns regarding
their tolerance (8). Particularly given the high morbidity related to both early and
late RV dysfunction post LVAD implantation, optimizing medical therapy has
becomes a controversial dilemma. Whether beta blocker therapy is beneficial or
detrimental for RV dysfunction after LVAD implantation has not been determined.
Beneficial effects of beta blockers in VAD patients have preliminarily been
suggested in a recent abstract (9), however published data on the potential
benefits of beta blockers and other heart failure therapy remains scarce. With the
rising cohort of LVAD patients each year (10), there is an increasing need for data
to understand the post-implantation optimum medical therapy that will result in the
best outcomes. We aimed to determine the effect of heart failure medical therapy
on the outcomes and adverse events in patients implanted with an LVAD at a
tertiary heart failure center.

Methods
Study population:
We performed a retrospective review of consecutive patients implanted with a
continuous flow LVAD-HeartMate II(Abbott, Abbott Park, IL) or Heart-Ware
(Medtronic, Minneapolis, MN), between January 2012 and December 2015 at a
tertiary care facility. Appropriate Institutional Review Board exemption was
obtained. Exclusion criteria included patients with their first LVAD placed prior to
2012 with re-implantation in the study period, an LVAD placed elsewhere, or
death/transplant within 6 months of implant (as these patients would not have data
available for collection at 6 months post implant). Key patient demographics and
echocardiographic variables were collected prior to-implant and 6 months after
implantation and key laboratory findings were collected pre implant, 6 months, and
12 months post LVAD-implant. Medication use and doses including beta-blocker in
metoprolol equivalent, angiotensin converting enzyme inhibitor (ACEinh) or
angiotensin receptor blockers (ARBs) in lisinopril equivalent, loop diuretics in
bumetanide equivalent, calcium channel blockers in amlodipine equivalent,
spironolactone, metolazone, hydralazine and nitrate use before implant, and at 6
and 12 months post-implant were collected. Heart failure and other medication use
was at the discretion of the advanced heart failure team based on individual
practice pattern and patient tolerance, and were often initiated as early as implant
admission or on early outpatient follow-up. Data on mortality and heart failure
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hospitalizations were collected from 6 to18 months post-implant (the 12 month
study window). Loss of patients to follow-up or missing follow-up data was
expected to be rare, as our facility is the only LVAD center in the area and we are
notified when our patients present elsewhere and routinely transfer LVAD patients
to our facility.
Echocardiographic (echo) data at 6 months post-implant was collected
retrospectively from reports. Echocardiograms were routinely performed at this
time frame as per our program protocols, and only echocardiograms performed
during outpatient follow up (in compensated state) were included. Assessment of
chamber size or function was based on the American Society of Echo guidelines
(11). Right atrial pressure was derived through echocardiographic assessment.
Not all echo variables were available on all patients due to poor image quality or
uninterpretable data and these data points were excluded from the study. Variable
that were not available were left as missing from data analysis. Congestive heart
failure (CHF) hospitalization was defined as admission secondary to fluid overload
with signs and symptoms requiring hospital-based medical treatment with
diuretics, occurring between 6-18 months after implantation. Mean arterial
pressure was reported based on program protocols using the mean pressure
obtained from an automated non-invasive measurement or a Doppler.
Statistical analysis:
Forward and backward conditional multivariate logistic regression analysis was
performed using demographic, medication and echocardiography data to identify
predictors of hospitalization and mortality. The variables used for the above
analysis included age, gender, diabetes, individual medication use, mean arterial
pressures, serum creatinine. Significance was defined at p-value ≤0.05.
IBM SPSS (version 19.0, SPSS Corp, Chicago, IL, USA) was used for statistical
analysis. Qualitative data is presented as frequencies and quantitative data as
mean ± standard deviation. Categorical variables were compared by using Chisquare test, and continuous variables were compared using Student’s t-test.
Paired t-test was used for numerical variables and McNemar test was used for
nominal variables for before and after implantation comparison. Prevalence and
percentages in the table represent patients with available and interpretable data
for each variable. Microsoft Excel 2013 was used for building charts and figures.

Results
In total, 138 patients had an LVAD placed and were discharged between January
2012 and December 2015, of which 9 patients underwent LVAD placement twice
in the study period and 31 patients were also excluded based on the exclusion
criteria (Figure 1). Thus, 98 patients (58 HeartMate II, 40 HeartWare) were
identified for inclusion into the study.
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Figure 1. Selection criteria for the study
Paired comparison of individual patients (before and after implant) is summarized
in Table 1.
Table 1. Paired-statistic comparison of patients before and 6 months after
LVAD implantation

Pre-implant
NYHA class 3 & 4 patients (n) 98 (100%)
Creatinine (mg/dL)
1.36 ± 0.56
Albumin(g/dL)
3.37 ± 0.49
Bilirubin (mg/dL)
1.56 ± 1.22
LDH(U/L)
224 ± 130.36
ProBNP (pg/mL)
4670.86 ± 3728.55
Greater than moderate AI (n)
23 (31.5%)
Greater than moderate MR (n) 37 (40%)
Greater than moderate TR (n) 20 (22%)
RA pressure (mm Hg)
12.82 +- 4.97
Greater than moderate RV
28 (40.6%)
enlargement(n)
Greater than moderate RV
47 (64.4%)
dysfunction (n)
LVEDD (cm)
7.08 +- 1.25

6 months
3 (3%)
1.36 ± 0.75
3.68 ± 0.51
1.19 ± 2.90
225.9 ± 72.40
2538.06 ± 4052.37
11 (15%)
20 (27%)
9 (12%)
11.00 +- 4.47
37 (53.6%)

P-value
0.01
0.79
0.01
0.32
0.69
0.01
0.02
0.15
0.07
0.04
0.16

55 (75.3%)

0.20

6.30 +- 1.37

0.01

Mean patient age was 57 ± 14 years and 79 patients (81%) were male. The cause
of heart failure was ischemic in 41 patients (61%) and 69 patients (70%) were
implanted as destination therapy. On LVAD support, the mean arterial pressure
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was 89 ± 13 mmHg at 6 months and 85 ± 12 mmHg at 12 months. At 6 and 12
months, only 3% and 4% of patients respectively were New York Heart
Association Class III and IV. There was a trend towards more RV dilation and
dysfunction on the 6 month echocardiogram compared to baseline, although this
did not meet statistical significance. A total of 14 (14%) patients were hospitalized
with CHF exacerbation and 8 patients (8%) died during the 6-18 months of follow
up.
The frequency of use of diuretics and heart failure medications as well as the
equivalent doses used pre implant, and at 6 and 12 months post-LVAD is shown in
Table 2.
Table 2: Use of GDMT, diuretics, and calcium-channel blockers (CCB) prior
to and post LVAD implant.
Medications

Pre-implant

6 months

12 months

Metolazone (n)

22 (23.2%)

9 (9.2%)

11 (12.9%)

Spironolactone (n)

62 (63.9%)

53 (54.1%)

40 (47.6%)

Beta blocker (n)

76 (77.6%)

72 (73.5%)

71 (84.5%)

ACEinh/ARB (n)

53 (54.1%)

59 (60.8%)

55 (66.3%)

Loop Diuretic (n)

88 (90.7%)

56 (58.1%)

47 (56%)

Nitrates (n)

11 (11.3%)

6 (6.1%)

5 (6%)

Hydralazine (n)

10 (10.3%)

35 (36.1%)

35 (41.7%)

CCB (n)

1 (1%)

14 (14.3%)

13 (15.7%)

Aspirin (n)

77 (78.6%)

91 (92.9%)

75 (89.3%)

Bumex equivalent (mg)

3.06 +- 2.04

1.26 +- 1.77

1.41 +- 2.01

Metoprolol equivalent (mg)

64.05 +- 66.93

81.66 +- 104.53 103.07 +- 122.30

Lisinopril equivalent (mg)

6.53 +- 11.76

16.40 +- 37.27

14.88 +- 38.20

Figure 2 shows the percentage of patients on various heart failure and antihypertensive medications before and after implantation. Figure 3 depicts the
number of medications prescribed to patients during the same time period (from 0
to ≥4 medications). While the use of loop diuretics decreased from pre-implant to
post-implant, more than 50% of patients continued to require loop diuretics at 6
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and 12 months post implant. Thiazide diuretic remained similar pre and post
implant. The use of beta-blockers, ACEinh/ARBs, and spironolactone,
Hydralazine and calcium channel blockers was relatively high post-LVAD at our
center. Figure 4 describes the trend of beta-blocker, ACEinh/ARB and loop diuretic
dosage prescription before and after implantation. The rate of pre-LVAD medical
therapy use was similar compared to prior advanced heart failure cohorts.

Figure 2: Use of GDMT, diuretics, and CCB prior to and post LVAD implant

Figure 3: Number of GDMT meds and CCB prescribed prior to and post
LVAD implantation
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Figure 4: Trend of medication doses pre and post-implant
Table 3 depicts the demographic, laboratory, echocardiographic and outcome data
of patients on and off beta blockers, ACEinh/ARB, and spironolactone. Patients on
BBs were younger and more likely to be men and patients on ACEinh/ARB were
younger and had better renal function, though the key laboratory and echo
characteristics were otherwise similar between those on and off these therapies.
Blood pressures at 6 and 12 months were not significantly different among patients
on versus off medical therapy (data not shown), as therapy was often titrated to
achieve a desired blood pressure.
At 6 months post-implantation, 72 patients (73%) (44 HeartMate II, 28 Heart-Ware)
were on beta-blockers with a daily metoprolol equivalent dose of 82 mg (± 105)
mg. Beta-blocker use was similarly distributed among patients irrespective of the
severity of the underlying RV dilation or dysfunction. Beta blockers at 6 months
were used in 74%, 68%, and 78% of patients with normal/mild, moderate, or
greater than moderate degree of RV dysfunction respectively based on the 6
month echo. Likewise, beta blockers were used in 82%, 64% and 71% of patients
with normal/mild, moderate, or greater than moderate degree of RV dilation
respectively based on the 6 month echo. Despite a significant prevalence of RV
dilation and dysfunction in the cohort, there was no significant difference in heart
failure hospitalizations with BB use (14% vs 15%) and instead a trend towards less
deaths in those on BB (6% vs 15%). Patients on beta-blockers also had
significantly lower proBNP at 6 months (1915 ± 2860 vs 4217 ± 5983 pg/mL, p=
0.01) and a trend towards lower BNP at 12 months (2260 ± 4538 vs 5188 ± 10590
pg/mL, p= 0.08).
The VAD Journal: https://doi.org/10.13023/vad.2018.09
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Table 3 A: Comparison of variables on and off GDMT medications, all
variables correlate with 6 month data unless specified

Age (years)
Males (n)
Ischemic
cardiomyopathy (n)
MAP (mm Hg)
Creatinine (mg/dL)
Bilirubin (mg/dL)
LDH (U/L)
Albumin (g/dL)
proBNP (at 6 months)
pg/ml
proBNP (at 12
months) pg/ml
LVEDD (cm.)
RA pressure (mm Hg)
Greater than
moderate AI (n)
Greater than
moderate MR (n)
Greater than
moderate TR (n)
Greater than
moderate RV dilation
(n)
Greater than
moderate RV
dysfunction (n)
CHF hospitalization
(n)
Death (n)

Beta-Blocker therapy
On therapy Off therapy
Pvalue
55 ±14
63 ± 11
0.02
62 (86%)
17 (65%)
0.02
63%
62%
0.93

ACEinh/ARB therapy
On
Off
Ptherapy
therapy
value
54 ±14
62 ± 12
0.04
47 (80%) 32 (84%) 0.57
63%
63%
0.96

87.69 ±
13.8
1.4 ± 0.7
0.9 ± 0.4
225 ± 78
3.7 ± 0.5
1915 ±
2860
2260 ±
4538
6.5 ±1.4
10 ± 4
8 (14%)

90.81 ± 11.8

0.31
0.78
0.25
0.79
0.08
0.01

5188 ±
10590
5.7 ± 1.2
11 ± 4
3 (16%)

0.08
0.03
0.67
0.85

89.08 ±
13.4
1.7 ± 1.1
1.1 ± 1.0
233 ± 63
3.4 ± 0.6
4715 ±
5784
5590 ±
10015
6.3 ± 1.0
12 ± 5
7 (18%)

0.78

1.4 ± 0.8
1.1 ± 1.2
229 ± 53
3.5 ± 0.6
4217 ± 5983

88.31 ±
13.4
1.1 ± 0.3
1.2 ± 3.7
221 ± 78
3.8 ± 0.4
1186 ±
1106
1356 ±
1280
6.3 ±1.5
9±3
4 (6%)

14 (26%)

6 (32%)

0.63

9 (21%)

10 (35%)

0.20

6 (11%)

3 (15%)

0.64

5 (11%)

3 (11%)

0.97

10 (71.4%)

4 (28.6%)

0.28

8 (17%)

6 (22%)

0.71

28 (77.8%)

8 (22.2%)

0.75

22 (49%)

14 (50%)

0.92

10 (14%)

4 (15%)

0.85

8 (14%)

6 (16%)

0.76

4 (6%)

4 (15%)

0.12

1 (2%)

7 (18%)

0.01

The VAD Journal: https://doi.org/10.13023/vad.2018.09

0.01
0.91
0.43
0.01
0.01
0.01
0.90
0.03
0.06

Page 9 of 17

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Table 3 B: Comparison of variables on and off other spironolactone, all
variables correlate with 6 month data unless specified

Age (years)
Males (n)
Ischemic cardiomyopathy (n)
MAP (mm Hg)
Creatinine (mg/dL)
Bilirubin (mg/dL)
LDH (U/L)
Albumin (g/dL)
proBNP (at 6 months) pg/ml
proBNP (at 12 months) pg/ml
LVEDD (cm.)
RA pressure (mm Hg)
Greater than moderate AI (n)
Greater than moderate MR (n)
Greater than moderate TR (n)
Greater than moderate RV
dilation (n)
Greater than moderate RV
dysfunction (n)
CHF hospitalization (n)
Death (n)

On spironolactone
(n=53)
53 ±14
41 (77%)
49%
87.13 ± 13.6
1.1 ± 0.4
1.4 ± 3.8
216 ± 76
3.8 ± 0.5
1813 ± 3058
1419 ± 1276
6.3 ±1.6
10 ± 4
4 (10%)
13 (33%)
5 (12%)
7 (18%)

Off spironolactone
(n=45)
63 ± 12
38 (84%)
78%
90.13 ± 13.0
1.5 ± 1.0
1.0 ± 1.0
239 ± 66
3.6 ± 0.5
3431 ± 4907
4635 ± 9116
6.1 ± 1.1
11 ± 5
7 (21%)
7 (21%)
4 (13%)
7 (22%)

P-value

19 (45%)

17 (53%)

0.50

7 (13%)
3 (6%)

7 (16%)
5 (11%)

0.74
0.32

0.01
0.37
0.03
0.27
0.01
0.49
0.12
0.09
0.05
0.02
0.60
0.20
0.14
0.28
0.93
0.71

At 6 months post implantation, 59 patients (60%) (32 HeartMate II, 27 Heart-Ware)
were on an ACE inhibitor or ARB, with an average lisinopril equivalent dose of 16
± 37mg/day.Although patients on an ACE inhibitor had worse NYHA Class prior to
LVAD implantation, they had significantly lower proBNPs at 6 and 12 months
following LVAD implant as well as a lower RA pressure compared to those not on
an ACE inhibitor. Over the 6-18 month follow-up period, the mortality rate was 1/60
(2%) among patients on ACEinh/ARB and 7/38 (18%) among patients not on
ACEinh/ARB (p= 0.01). The beneficial effect on survival remained significant in
multivariate analyses accounting for age, gender, renal function, and concomitant
medication use (Odds ratio: 0.07, Confidence Interval 0.009-0.649, p = 0.018).
Key variables for patients with and without a CHF hospitalization between 6-18
months after LVAD implantation are shown in Table 4. Patient who experienced a
hospitalization were more likely to be on diuretic at 6 months (p= 0.021) and were
on a higherbumetanideequivalent dose than the non-hospitalized group (2.24 ± 2.2
vs 1.01±1.5mg, p= 0.002). In multivariate analysis including age, gender, renal
function, and medication use, diuretic use at 6 months remained a predictor of
subsequent CHF hospitalization (Odds ratio: 5.7, Confidence Interval 1.2-27.2, p =
The VAD Journal: https://doi.org/10.13023/vad.2018.09
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0.029). When echo parameters were included in the multivariate model, only RA
pressure of ≥ to 12.5 mmHg at 6 months remained predictive of subsequent CHF
hospitalizations (Odds ratio: 1.228, 95% Confidence Interval 1.040-1.451, p =
0.01).
Table 4: Six months patient characteristics and association with subsequent
heart failure hospitalization over the following 12 months
At 6 months

CHF hospitalization

P value

Yes

No

On metolazone(n)

4 (23%)

5 (6.1%)

0.02

On diuretic (n)

14 (82.3%)

42 (51.8%)

0.02

NYHA class 3 or 4 (n)

2 (11.7%)

1 (1.2%)

0.02

MAP (mm Hg)

86.33 ± 6.55

87.00 ± 13.37

0.865

Bumex equivalent (mg)

2.44 ± 2.23

1.01± 1.56

0.01

RA pressure (mm Hg)

13.57 ± 4.75

9.43 ± 3.78

0.01

Greater than moderate RV dilation (n)

8 (62%)

31 (50%)

0.44

Greater than moderate RV dysfunction (n)

10 (77%)

49 (74%)

0.83

Greater than moderate AI (n)

3 (25%)

8 (13%)

0.25

Greater than moderate MR (n)

3 (27%)

17 (27%)

0.99

Greater than moderate TR (n)

0 (0%)

9 (14%)

0.15

LVEDD (cm.)

6.40 ± 0.90

6.25 ± 1.39

0.72

Aortic valve opening (n)

4 (36%)

56 (47%)

0.50

There were 7 admissions for implanted defibrillator discharge but BB use was not
associated with any significant difference (p= 0.09 at 6 months and p= 0.23 at 12
months).Death between 6-18 months in our cohort occurred in 8 patients. Causes
included progressive renal failure/multi-organ failure (4 patients), withdrawal of
care/hospice (3 patients), PEA and presumed bacteremia (1 patient).

Discussion
The past decade has seen LVAD implantation become mainstream in the
management of advanced heart failure through significant improvement in the
reliability, safety and longevity of the pumps. With increasing demand and
unchanged availability of transplant-eligible hearts, LVAD implantation can be
expected to increase with time. In the 9 years of Interagency Registry for
The VAD Journal: https://doi.org/10.13023/vad.2018.09
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Mechanically Assisted Circulatory Support (INTERMACS) Registry, more than
15,000 patients have been implanted with an LVAD in 158 participating
institutions(10). However, there is no clear understanding and a surprising lack of
evidence about the role of heart failure therapy post LVAD implantation(2). Among
our cohort, the use of heart failure therapy post LVAD implantation appeared safe
and beneficial, which has important clinical implications for the medical
management of this growing group of patients.
Angiotensin inhibitors post LVAD
Here, we show, for the first time, that patients receiving an ACE inhibitor (despite
being in a worse NYHA Class prior to LVAD implantation in our series) had
significantly lower proBNPs at 6 monthsand 12 monthsfollowing LVAD implant and
better survival after LVAD implantation both in univariate and multivariate
analyses. Patients on an ACE inhibitor or ARB also had a subsequent lower RA
pressure compared to those not on an ACEinh/ARB suggesting a potential
beneficial effect on RV function.
There are several potential mechanisms to explain the beneficial clinical effects of
angiotensin system blockade post implantation. Use of ACEinh/ARB have been
reported to reverse myocardial remodeling(12) and arteriovenous malformation
related gastrointestinal bleeding(13) among post-LVAD patients, however efficacy
and mortality data have been lacking so far. In a retrospective study of 131
patients(13), use of ACEinh/ARB was an independent factor in reducing the risk of
significant gastrointestinal bleeding, including arteriovenous malformation
associated bleeding. In a study of myocardial biopsy samples pre and post-LVAD
implantation, Klotz et al reported low myocardial collagen content and stiffness
post-LVAD implantation in patients prescribed angiotensin system blockers,
possibly suggesting reverse remodeling in these patients(12). The findings of the
present study suggest that these or other mechanisms may have clinical utility
through improved outcomes including survival. These finding will need to be
validated however in larger patient cohorts, such as INTERMACS.
Beta blockade post LVAD
Our fairly well characterized cohort also suggested that beta blockers are
potentially beneficial post LVAD implantation. Despite a population with a
significant prevalence of RV dilation and dysfunction, patients on beta-blockers
had a significantly lower proBNP 6 months after LVAD implantation and a trend
towards a lower BNP at 12 months. Beta blockers furthermore appear safe as
there was no significant difference in the frequency of heart failure hospitalization
with beta blocker use and a trend towards lower mortality in those on beta
blockers.
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Beta-blockers are widely used for left ventricular failure but their role in right
ventricular failure (and therefore their role post LVAD implantation) remains
unestablished with even a suggestion of a negative effect(8) Although the possible
negative effect is a widely held belief, the evidence for it is extremely sparse.
Pulmonary arterial hypertension is considered a relative contraindication for betablocker use due to concerns of a possible negative effect on hemodynamics and
exercise capacity. However this is only based on a small study of 10 patients with
porto-pulmonary hypertension in which withdrawal of propranolol was associated
with improved exercise tolerance and on one case report (14-16). Furthermore
more recent literature in patients with pulmonary hypertension and congenital
heart disease suggests otherwise with improvements in RV re-modelling(17) and
RV end-diastolic volumes(18) with beta blocker therapy, and such therapy having
no deleterious effect on exercise capacity or mortality (18,19). Beta blockers have
been shown to improve RV function and prevent myocardial re-modelling in animal
models of pulmonary hypertension(17,20) as well as to reverse the characteristic
‘molecular signature’ of RV failure(21). In humans a small single arm study of beta
blockers in patients post correction of transposition of the great arteries showed
improvements in symptoms, quality of life and RV ejection fraction(22).
Furthermore more recently, a prospective cohort study of 94 PAH patients found
no increase in adverse clinical or hemodynamic consequences in the 285 patients
on beta blockers for other cardiac co-morbidities(19). However we continue to lack
large prospective trials to prove the role of beta-blockers in RV failure(23). Our
data certainly suggests no increase in adverse events with beta blocker use on
clinical right ventricular function with potential beneficial clinical effects.
Another potential mechanism of beta blocker benefit is through arrhythmia
prevention. The risk of ventricular arrhythmia is significant after LVAD placement
and arrhythmia can worsen RV function. Early beta-blockade is certainly
suggested in patients with pre-or post-LVAD history of arrhythmias(24), and one
mechanism of the benefit can be through RV preservation(25).
Myocardial Recovery
Mechanical unloading with an LVAD can lead to sufficient reverse remodeling and
improvement in myocardial function to allow explantation of the device and leave
the patient with a good quality of life. However the rate at which this occurs has
been highly variable and it is likely that neuro-hormonal antagonists, beta blockers,
and aldosterone antagonists all significantly facilitate ventricular reverse
remodeling and reduce fibrosis leading to myocardial recovery and subsequent
explantation in a higher proportion of cases after LVAD support. LVAD patients
continue to have pathological re-modelling and increase in myocardial
stiffness(26). Two prospective studies(6,7) have suggested that aggressive uptitration of reverse remodeling heart failure therapy including high dose ACEinh
and beta-blockers is associated with improvement in severe heart failure from nonThe VAD Journal: https://doi.org/10.13023/vad.2018.09
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ischemic cardiomyopathy and successful device explantation in patients through
reversal of the pathological re-modelling. The demonstration that angiotensin
system inhibitors and beta blockers appear safe in LVAD recipients may allow for
their greater use and therefore greater possibility of eventual explantation. Prior to
LVAD implantation, patients usually become intolerant to these therapies due to
hypotension and renal failure (from the low cardiac output), but the improved flow,
better blood pressure and improved renal function provided by the LVAD may
allow up-titration of these drugs to very high doses thus making the LVAD a
platform for myocardial recovery.
The trend towards a greater degree of RV dilation and dysfunction on the postVAD echocardiograms at 6 months is of unclear significance. Possible
explanations include an increase in venous return due to improved left sided
cardiac output and potential effects of LV suction on the ventricular septum.
Clinical Implications
Similar to our findings, a recent study from the INTERMACS data(2) noted an
increase in prescription of ACEinh, ARBs and beta-blockers 3 months and 6
months post-implantation. While the use of loop diuretics declined after
implantation in the INTERMACS cohort, the number still remained considerably
high (>55% patients). The study also reported highest beta-blocker use in younger
patients which is similar to our present study. These findings are similar to the
practice pattern in our hospital, making our results potentially applicable to larger
populations. Not all patients in the INTERMACS cohort were prescribed GDMT
post-implant and this could be indicative of individual patient intolerance to these
medications but also likely signify the uncertainty and lack of guidelines. Currently,
the International Society for Heart and Lung Transplantation (ISHLT) recommends
utilization of heart failure medications (ACEinh, ARBs and beta-blockers) for blood
pressure or tachyarrhythmia management(27) but no recommendation has been
made for their continued utilization in LVAD patients for management of heart
failure per se. ACE/ARB and beta blockers will also lower blood pressure in LVAD
patients which will have a secondary beneficial effect by lowering the stroke
risk(5). Our current results highlight a potential beneficial role for these therapies
above and beyond blood pressure and arrhythmia prevention by demonstrating
both safety and potential efficacy in our cohort.
We also found that risk of heart failure hospitalization during follow up was
associated with diuretic use and with higher RA pressure(table 4), suggesting a
possible association with “late RV failure”. These findings may have important
implications for optimizing medical therapy post LVAD implantation and for
identifying patients at highest risks for adverse events.
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Limitations
The limitations of the study include the retrospective design and single facility. The
study was underpowered to perform significant subset analysis or present a
prediction model. This study aimed at understanding the outpatient practice
pattern in LVAD implanted patients and evaluating the safety of continued
prescription of beta-blockers and other heart failure medical therapies. Also the
difference in prescription of medications (ACEinh and diuretics) in subgroup
analysis for predictors may be confounded by individual intolerance and not clearly
indicate efficacy. Medication use at the 6 month time-point only was used for
statistical analysis and the use or duration of heart failure therapy prior to or after
the 6 month time frame may have varied among patients. The position of the
ventricular septum was not addressed on all studies.

Conclusion
In conclusion this study presents a well characterized cohort of advanced heart
failure patients post LVAD implantation, with several key findings. We demonstrate
that the use of angiotensin system inhibitors appeared to be associated with lower
pro-BNP, RA pressure, and most importantly improved survival. We also
demonstrate that beta blocker therapy appears safe, including in patients with
significant right ventricular dysfunction, and may be beneficial in patients post
LVAD implantation by being associated with a lower pro-BNP. The use of betablocker and angiotensin system inhibitors in LVAD patients need further
investigation, however, this study provides evidence to support their use post
LVAD implantation. In general, these drugs may not be used as prolifically as they
should be, most likely due to the lack of evidence in this patient population. The
current study highlights that the risks of heart failure therapies may be overexaggerated while the benefits may be underappreciated.
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